Skip to Content

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

A phase III study unveils that an oral fixed-dose combination of decitabine and cedazuridine, offers a new, effective oral treatment route for AML patients unable to undergo standard chemotherapy.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top